Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational Accepts healthy volunteers

Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders

NCT01212016
Conditions
Eosinophilic Gastroenteritis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
1 Year to 3 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Conditions
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions
PVX-108, Placebo
Biological
Lead sponsor
Aravax Pty Ltd
Industry
Eligibility
4 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Completed Phase 1 Interventional Results available

Boiled Peanut Oral Immunotherapy

NCT04090203
Conditions
Peanut Hypersensitivity
Interventions
Boiled Peanut Powder
Drug
Lead sponsor
Alton Melton
Other
Eligibility
1 Year to 16 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 55 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Conditions
Peanut Allergy, Food Allergy
Interventions
Omalizumab, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
Interventions
Liquid peanut extract (Peanut SLIT)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Peanut Allergy, Milk Allergy, Egg Allergy
Interventions
Oral food challenge
Procedure
Lead sponsor
National Jewish Health
Other
Eligibility
3 Years to 21 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Peanut Allergy (PMIT)

NCT00597675
Conditions
Food Hypersensitivity
Interventions
Peanut OIT, Placebo
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Conditions
Peanut Allergy
Interventions
INT301, Placebo
Drug
Lead sponsor
Intrommune Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Belleville, New Jersey • Riverdale, New Jersey
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
49
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 39 more
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy

NCT01897077
Conditions
Peanut Allergy
Interventions
Peanut Dissolving Film
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Peanut Allergy
Interventions
Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Conditions
Allergy, Peanut
Interventions
LOU064, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Conditions
Peanut Allergy
Interventions
walnut powder
Drug
Lead sponsor
Jonathan Spergel
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Peanut Allergy
Interventions
ASP0892 Intradermal, ASP0892 Intramuscular, Placebo Intradermal, Placebo Intramuscular
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more
Conditions
Peanut Allergy
Interventions
Epicutaneous skin prick testing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina